Fulcrum Asset Management LLP Acquires 2,418 Shares of Eli Lilly and Company $LLY

Fulcrum Asset Management LLP boosted its stake in shares of Eli Lilly and Company (NYSE:LLY) by 27.9% in the third quarter, Holdings Channel reports. The institutional investor owned 11,093 shares of the company’s stock after purchasing an additional 2,418 shares during the period. Eli Lilly and Company accounts for approximately 0.6% of Fulcrum Asset Management LLP’s portfolio, making the stock its 20th biggest position. Fulcrum Asset Management LLP’s holdings in Eli Lilly and Company were worth $13,141,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also added to or reduced their stakes in the stock. Allspring Global Investments Holdings LLC boosted its holdings in Eli Lilly and Company by 5.0% in the third quarter. Allspring Global Investments Holdings LLC now owns 330,482 shares of the company’s stock worth $380,005,000 after acquiring an additional 15,758 shares in the last quarter. rebel Financial LLC bought a new position in shares of Eli Lilly and Company during the third quarter valued at $234,000. StoneRidge PMG Advisors LLC purchased a new position in shares of Eli Lilly and Company in the 3rd quarter worth about $1,906,000. Beverly Hills Private Wealth LLC raised its position in shares of Eli Lilly and Company by 15.4% in the 3rd quarter. Beverly Hills Private Wealth LLC now owns 1,147 shares of the company’s stock worth $1,326,000 after purchasing an additional 153 shares during the last quarter. Finally, Brickley Wealth Management raised its position in shares of Eli Lilly and Company by 23.8% in the 3rd quarter. Brickley Wealth Management now owns 302 shares of the company’s stock worth $349,000 after purchasing an additional 58 shares during the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Trading Up 4.4%

NYSE LLY opened at $1,413.22 on Tuesday. The company has a market capitalization of $1.33 trillion, a price-to-earnings ratio of 45.87, a price-to-earnings-growth ratio of 1.77 and a beta of 0.40. The company’s 50-day simple moving average is $1,220.13 and its two-hundred day simple moving average is $1,102.83. The company has a debt-to-equity ratio of 1.17, a quick ratio of 1.00 and a current ratio of 1.39. Eli Lilly and Company has a one year low of $850.51 and a one year high of $1,453.00.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Thursday, October 29th. The company reported $7.48 EPS for the quarter, topping analysts’ consensus estimates of $5.71 by $1.77. Eli Lilly and Company had a net margin of 31.90% and a return on equity of 86.76%. The company had revenue of $24.40 billion during the quarter, compared to the consensus estimate of $22.58 billion. During the same quarter in the previous year, the firm posted $7.02 earnings per share. Eli Lilly and Company’s revenue for the quarter was up 38.6% compared to the same quarter last year. Equities analysts forecast that Eli Lilly and Company will post 35.70 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, December 10th. Investors of record on Friday, November 13th will be paid a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a dividend yield of 0.5%. The ex-dividend date is Friday, November 13th. Eli Lilly and Company’s payout ratio is 22.46%.

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: In a Phase 3 trial, Foundayo (orforglipron) significantly reduced obstructive sleep apnea severity in adults with obesity or overweight. Lilly reported up to an average 44% reduction in breathing interruptions and said it plans to seek U.S. FDA approval for the indication by year-end 2026. An additional use could expand the pill’s commercial opportunity and help it compete with Novo Nordisk’s obesity treatments. Article: Eli Lilly’s Foundayo obesity pill eases sleep apnea in late-stage trial
• Positive Sentiment: Jefferies raised its LLY price target to $1,700 from $1,610 and reiterated a Buy rating, signaling continued analyst confidence in the company’s growth outlook. Article: Jefferies raises Eli Lilly price target
• Positive Sentiment: Lilly is expanding digital access to Zepbound and Foundayo through telehealth partnerships with Hims & Hers and LifeMD, potentially broadening the reach of its branded obesity medicines. Article: Eli Lilly opens digital access to obesity drugs
• Negative Sentiment: The FDA issued new warnings about a potential serious eye risk associated with GLP-1 drugs, including Zepbound. The safety alert may raise concerns for patients and prescribers, although the reports provided no Lilly-specific change to the drug’s safety profile. Article: FDA orders new eye-risk warnings for Ozempic and Zepbound

Insider Buying and Selling at Eli Lilly and Company

In related news, EVP Patrik Jonsson sold 6,500 shares of the firm’s stock in a transaction on Monday, August 17th. The stock was sold at an average price of $1,175.10, for a total value of $7,638,150.00. Following the completion of the transaction, the executive vice president owned 54,147 shares in the company, valued at $63,628,139.70. This trade represents a 10.72% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Anat Hakim sold 5,000 shares of Eli Lilly and Company stock in a transaction dated Monday, November 2nd. The stock was sold at an average price of $1,402.52, for a total value of $7,012,600.00. Following the sale, the executive vice president directly owned 4,137 shares of the company’s stock, valued at approximately $5,802,225.24. This represents a 54.72% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 0.14% of the company’s stock.

Analyst Ratings Changes

A number of analysts have recently issued reports on the stock. Guggenheim increased their price objective on shares of Eli Lilly and Company from $1,273.00 to $1,284.00 and gave the stock a “buy” rating in a research note on Friday, September 18th. Weiss Ratings downgraded shares of Eli Lilly and Company from a “buy (b+)” rating to a “buy (b)” rating in a report on Friday, October 30th. Cantor Fitzgerald increased their price target on Eli Lilly and Company from $1,440.00 to $1,600.00 and gave the stock an “overweight” rating in a research note on Monday, November 2nd. Truist Financial reissued a “buy” rating and set a $1,612.00 price target (up from $1,376.00) on shares of Eli Lilly and Company in a report on Friday, October 30th. Finally, The Goldman Sachs Group restated a “buy” rating and issued a $1,413.00 price objective on shares of Eli Lilly and Company in a research report on Tuesday, October 20th. One investment analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $1,416.64.

Eli Lilly and Company Company Profile

Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for people and animals. Its work spans areas including diabetes and obesity, cancer, immunology, neuroscience and pain management.

The company’s medicines include treatments for diabetes and obesity, such as Mounjaro and Zepbound, as well as products for cancer and other conditions. Lilly also conducts research into new medicines and invests in the development of treatments across its therapeutic areas.

Founded in Indianapolis in 1876 by Colonel Eli Lilly, the company is headquartered in the city and serves patients in markets around the world.